Sirtuin modulators: Mechanisms and potential clinical implications

Current Medicinal Chemistry

Volumn 19, Issue 15, 2012, Pages 2414-2441

  Sanchez Fidalgo S ^a   Villegas, I ^a   Sanchez Hidalgo M ^a   De La Lastra, C Alarcón ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Aging; Cancer; Cardiovascular diseases; Inflammation; Metabolic diseases; Neuromodulation; Sirtuin activators; Sirtuin inhibitors; Sirtuins

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE ACETATE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENZYME ACTIVATOR; ENZYME INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; RESVERATROL; SILENT INFORMATION REGULATOR PROTEIN 2; SIRTUIN 1; SIRTUIN 2; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7; SRT 1460; SRT 1720; SRT 2183; STAT3 PROTEIN; STROMELYSIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOXP3; TUMOR PROMOTER; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AGING; ALZHEIMER DISEASE; ARTICLE; ASPHYXIA; ATHEROSCLEROSIS; CANCER CELL CULTURE; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; DIABETES MELLITUS; DNA DAMAGE; DNA REPAIR; ENCEPHALITIS; ENZYME ACTIVITY; HEART ARREST; HEPATITIS; HOMEOSTASIS; HUMAN; IMMUNITY; INFLAMMATION; KNOCKOUT MOUSE; METABOLIC DISORDER; NEOPLASM; NERVE DEGENERATION; NEUROMODULATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REGULATORY T LYMPHOCYTE;

EID: 84860677209     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800269272     Document Type: Article

References (287)

1. Rine, J.; Strathern, J. N.; Hicks, J. B.; Herskowitz, I. A suppressor of matingtype locus mutations in Saccharomyces cerevisiae: Evidence for and identification of cryptic mating-type loci. Genetics, 1979, 93 (4), 877-901. (Pubitemid 10077472)
2. Haigis, M.C.; Guarente, L.P. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev., 2006, 20 (21), 2913-2921. (Pubitemid 44771725)
3. Haigis, M.C.; Sinclair, D.A. Mammaliansirtuins: Biological insights and disease relevance. Annu. Rev. Pathol., 2010, 5, 253-295.
4. Szczepankiewicz, B.G.; Ng, P.Y. Sirtuin modulators: Targets for metabolic diseases and beyond. Curr.Top Med. Chem., 2008, 8 (17), 1533-1544.
5. Milner, J. Cellular regulation of SIRT1. Curr. Pharm. Des., 2009, 15 (1), 39-44.
6. Neugebauer, R.C.; Sippl, W.; Jung, M. Inhibitors of NAD+ dependent histone deacetylases (sirtuins). Curr. Pharm. Des., 2008, 14 (6), 562-573. (Pubitemid 351516879)
7. Finkel, T.; Deng, C.X.; Mostoslavsky, R. Recent progress in the biology and physiology of sirtuins. Nature, 2009, 460 (7255), 587-591.
8. Liou, G.G.; Tanny, J.C.; Kruger, R.G.; Walz, T.; Moazed, D. Assembly of the SIR complex and its regulation by O-acetyl-ADP-ribose, a product of NAD-dependent histone deacetylation. Cell, 2005, 121 (4), 515-527. (Pubitemid 40720006)
9. Bitterman, K.J.; Anderson, R.M.; Cohen, H.Y.; Latorre-Esteves, M.; Sinclair, D.A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast sir2 and human SIRT1. J. Biol. Chem., 2002, 277 (47), 45099-45107. (Pubitemid 36159111)
10. Jackson, M.D.; Schmidt, M.T.; Oppenheimer, N.J.; Denu, J.M. Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J. Biol. Chem., 2003, 278 (51), 50985-50998. (Pubitemid 38020332)
11. Sauve, A.A.; Schramm, V.L. Sir2 regulation by nicotinamide results from switching between baseexchange and deacetylation chemistry. Biochemistry, 2003, 42 (31), 9249-9256. (Pubitemid 36959231)
12. Sauve, A.A.; Moir, R.D.; Schramm, V.L.; Willis, I.M. Chemical activation of Sir2-dependent silencing byrelief of nicotinamide inhibition. Mol. Cell, 2005, 17 (4), 595-601. (Pubitemid 40269123)
13. Houtkooper, R. H.; Canto, C.; Wanders, R. J.; Auwerx, J. The secret life of NAD+: An oldmetabolite controlling new metabolic signaling pathways. Endocr. Rev., 2010, 31 (2), 194-223.
14. Saunders, L.R.; Verdin, E. Sirtuins: Critical regulators at the crossroads between cancer and aging. Oncogene, 2007, 26 (37), 5489-5504. (Pubitemid 47255930)
15. Michishita, E.; McCord, R.A.; Berber, E.; Kioi, M.; Padilla-Nash, H.; Damian, M.; Cheung, P.; Kusumoto, R.; Kawahara, T.L.; Barrett, J.C.; Chang, H.Y.; Bohr, V.A.; Ried, T.; Gozani, O.; Chua, K.F. SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature, 2008, 452 (7186), 492-496. (Pubitemid 351450840)
16. Ford, E.; Voit, R.; Liszt, G.; Magin, C.; Grummt, I.; Guarente, L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev., 2006, 20 (9), 1075-1080.
17. Nakagawa, T.; Lomb, D.J.; Haigis, M.C.; Guarente, L. SIRT5 Deacetylatescarbamoyl phosphatesynthetase 1 and regulates the urea cycle. Cell, 2009, 137 (3), 560-570.
18. Nakagawa, T.; Guarente, L. Sirtuins at a glance. J. Cell Sci., 2011, 124 (Pt 6), 833-838.
19. Hummasti, S.; Hotamisligil, G.S. Endoplasmic reticulum stress and inflammation in obesity and diabetes. Circ. Res., 2010, 107 (5), 579-591.
20. Gallí, M.; Van Gool, F.; Leo, O. Sirtuins and inflammation: Friends or foes? Biochem. Pharmacol., 2011, 81 (5), 569-576.
21. Canto, C.; Gerhart-Hines, Z.; Feige, J.N.; Lagouge, M.; Noriega, L.; Milne, J.C.; Elliott, P.J.; Puigserver, P.; Auwerx, J. AMPK regulates energyexpenditure by modulating NAD+ metabolism andSIRT1 activity. Nature, 2009, 458 (7241), 1056-1060.
22. Iwabu, M.; Yamauchi, T.; Okada-Iwabu, M.; Sato, K.; Nakagawa, T.; Funata, M.; Yamaguchi, M.; Namiki, S.; Nakayama, R.; Tabata, M.; Ogata, H.; Kubota, N.; Takamoto, I.; Hayashi, Y.K.; Yamauchi, N.; Waki, H.; Fukayama, M.; Nishino, I.; Tokuyama, K.; Ueki, K.; Oike, Y.; Ishii, S.; Hirose, K.; Shimizu, T.;Touhara, K.; Kadowaki, T. Adiponectinand AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature, 2010, 464 (7293), 1313-1319.
23. Rodgers, J.T.; Lerin, C.; Haas, W.; Gygi, S.P.; Spiegelman, B.M.; Puigserver, P. Nutrient control of glucosehomeostasis through a complex of PGC-1aand SIRT1. Nature, 2005, 434 (7029), 113-118. (Pubitemid 40349395)
24. Liu, Y.; Dentin, R.; Chen, D.; Hedrick, S.; Ravnskjaer, K.; Schenk, S.; Milne, J.; Meyers, D. J.; Cole, P.; Yates, J. 3rd; Olefsky, J.; Guarente, L.; Montminy, M.A. fasting inducible switch modulatesgluconeogenesis via activator/coactivator exchange. Nature, 2008, 456 (7219), 269-273.
25. Purushotham, A.; Schug, T.T.; Xu, Q.; Surapureddi, S.; Guo, X.; Li, X. Hepatocyte-specific deletionof SIRT1 alters fatty acid metabolism and results inhepatic steatosis and inflammation. Cell Metab., 2009, 9 (4), 327-338.
26. Mostoslavsky, R.; Chua, K.F.; Lombard, D.B.; Pang, W.W.; Fischer, M.R.; Gellon, L.; Liu, P.; Mostoslavsky, G.; Franco, S.; Murphy, M.M.; Mills, K.D.; Patel, P.; Hsu, J.T.; Hong, A.L.; Ford, E.; Cheng, H.L.; Kennedy, C.; Nunez, N.; Bronson, R.; Frendewey, D.; Auerbach, W.; Valenzuela, D.; Karow, M.; Hottiger, M.O.; Hursting, S.; Barrett, J.C.; Guarente, L.; Mulligan, R.; Demple, B.; Yancopoulos, G.D.; Alt, F.W. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell, 2006, 124 (2), 315-329. (Pubitemid 43121980)
27. Zhong, L.; Mostoslavsky, R. SIRT6: A master epigenetic gatekeeper of glucose metabolism. Transcr., 2010, 1(1), 17-21.
28. Xiao, C.; Kim, H.S.; Lahusen, T.; Wang, R.H.; Xu, X.; Gavrilova, O.; Jou, W.; Gius, D.; Deng, C.X. SIRT6 deficiency results in severe hypoglycemia by enhancing both basal and insulin-stimulated glucose uptake in mice. J. Biol. Chem., 2010, 285(47), 36776-36784.
29. Bordone, L.; Motta, M.C.; Picard, F.; Robinson, A.; Jhala, U.S.; Apfeld, J.; McDonagh, T.; Lemieux, M.; McBurney, M.; Szilvasi, A.; Easlon, E.J.; Lin, S.J.; Guarente, L. Sirt1 regulates insulin secretion byrepressing UCP2 in pancreatic βcells. PLoS. Biol., 2006, 4 (2), e31.
30. Haigis, M.C.; Mostoslavsky, R.; Haigis, K.M.; Fahie, K.; Christodoulou, D.C.; Murphy, A.J.; Valenzuela, D.M.; Yancopoulos, G.D.; Karow, M.; Blander, G.; Wolberger, C.; Prolla, T.A.; Weindruch, R.; Alt, F.W.; Guarente, L. SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic beta cells. Cell, 2006, 126 (5), 941-954. (Pubitemid 44321935)
31. Ahuja, N.; Schwer, B.; Carobbio, S.; Waltregny, D.; North, B.J.; Castronovo, V.; Maechler, P.; Verdin, E. Regulation of insulin secretion by SIRT4, a mitochondrial ADP-ribosyltransferase. J. Biol. Chem., 2007, 282 (46), 33583-33592. (Pubitemid 350159524)
32. Kemper, J.K.; Xiao, Z.; Ponugoti, B.; Miao, J.; Fang, S.; Kanamaluru, D.; Tsang, S.; Wu, S. Y.; Chiang, C.M.; Veenstra, T.D. FXR acetylation is normally dynamically regulated by p300 and SIRT1 butconstitutively elevated in metabolic disease states. Cell Metab., 2009,10 (5), 392-404.
33. Li, X.; Zhang, S.; Blander, G.; Tse, J.G.; Krieger, M.; Guarente, L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell, 2007, 28 (1), 91-106. (Pubitemid 47531974)
34. Picard, F.; Kurtev, M.; Chung, N.; Topark-Ngarm, A.; Senawong, T.; Machado De Oliveira, R.; Leid, M.; McBurney, M.W.; Guarente, L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-?. Nature, 2004, 429 (6993), 771-776. (Pubitemid 38833129)
35. Qiao, L.; Shao, J. SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-bindingproteinatranscriptional complex. J. Biol. Chem., 2006, 281 (52), 39915-39924. (Pubitemid 46041795)
36. Schug, T.T.; Li, X. Sirtuin1 in lipid metabolism and obesity. Ann. Med., 2011, 43 (3), 198-211.
37. Jing, E.; Gesta, S.; Kahn, C.R. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab., 2007, 6 (2), 105-114. (Pubitemid 47163621)
38. Hallows, W.C.; Lee, S.; Denu, J.M. Sirtuinsdeacetylate and activate mammalian acetyl-CoA synthetases. Proc. Natl. Acad. Sci. U.S.A., 2006, 103 (27), 10230-10235. (Pubitemid 44051149)
39. Giralt, A.; Hondares, E.; Villena, J.A.; Ribas, F.; Díaz-Delfin, J.; Giralt, M.; Iglesias, R.; Villarroya F. Peroxisome proliferator-activated receptor-gamma coactivator-1alphacontrols the transcription of the SIRT3 gene, an essential component of the thermogenic brown adipocyte phenotype. J. Biol. Chem., 2011, 286 (19), 16958-16966.
40. Hirschey, M.D.; Shimazu, T.; Goetzman, E.; Jing, E.; Schwer, B.; Lombard, D.B.; Grueter, C.A.; Harris, C.; Biddinger, S.; Ilkayeva, O.R.; Stevens, R.D.; Li, Y.; Saha, A.K.; Ruderman, N.B.; Bain, J.R.; Newgard, C.B.; Farese, R.V. Jr.; Alt, F.W.; Kahn, C.R.; Verdin, E. SIRT3 regulates mitochondrial fattyacid oxidation by reversible enzyme deacetylation. Nature, 2010, 464 (7285), 121-125.
41. Nasrin, N.; Wu, X.; Fortier, E.; Feng, Y.; Bare, O.C.; Chen, S.; Ren, X.; Wu, Z.; Streeper, R.S.; Bordone, L. SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells. J. Biol. Chem., 2010, 285 (42), 31995-32002.
42. Kim, H.S.; Xiao, C.; Wang, R.H.; Lahusen, T.; Xu, X.; Vassilopoulos, A.; Vazquez-Ortiz, G.; Jeong, W. I.; Park, O.; Ki, S. H.; Gao, B.; Deng, C.X. Hepatic-specific disruption of SIRT6 in mice results in fatty liverformation due to enhanced glycolysis and triglyceridesynthesis. Cell Metab., 2010, 12 (3), 224-236.
43. Choudhury, M.; Jonscher, K.R.; Friedman, J.E. Reduced mitochondrial function in obesity-associated fatty liver: SIRT3 takes on the fat. Aging (Albany NY), 2011, 3 (2), 175-178.
44. Medzhitov, R. Origin and physiological roles of inflammation. Nature, 2008, 454 (7203), 428-435.
45. Ruland, J. Return to homeostasis: Downregulation of NF-kB responses. Nat. Immunol., 2011, 12 (8), 709-714.
46. Wullaert, A.; Bonnet, M.C.; Pasparakis, M. NF-kB in the regulation of epithelial homeostasis and inflammation. Cell Res., 2011, 21 (1), 146-158.
47. Yeung, F.; Hoberg, J.E.; Ramsey, C.S.; Keller, M.D.; Jones, D.R.; Frye, R.A.; Mayo, M.W. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J., 2004, 23 (12), 2369-2380. (Pubitemid 38954844)
48. Yang, S.R.; Wright, J.; Bauter, M.; Seweryniak, K.; Kode, A.; Rahman, I. Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: Implications for chronic inflammation and aging. Am. J. Physiol. Lung Cell Mol. Physiol., 2007, 292, L567-L576.
49. Shen, Z.; Ajmo, J.M.; Rogers, C.Q.; Liang, X.; Le, L.; Murr, M.M.; Peng, Y.; You, M. Role of SIRT1 in regulation of LPS-or two ethanol metabolitesinduced TNF-alpha production in cultured macrophage cell lines. Am. J. Physiol.Gastrointest. Liver Physiol., 2009, 296, G1047-G1053.
50. Salminen, A.; Huuskonen, J.; Ojala, J.; Kauppinen, A.; Kaarniranta, K.; Suuronen, T. Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res. Rev., 2008, 7(2), 83-105. (Pubitemid 351418294)
51. Csiszar, A.; Smith, K.; Labinskyy, N.; Orosz, Z.; Rivera, A.; Ungvari, Z. Resveratrol attenuates TNF-alpha-induced activation of coronary arterial endothelial cells: Role of NF-kappaB inhibition. Am. J. Physiol. Heart Circ. Physiol, 2006, 291 (4), H1694-H1699. (Pubitemid 44497674)
52. Pfluger, P.T.; Herranz, D.; Velasco-Miguel, S.; Serrano, M.; Tschöp, M.H. Sirt1 protects against high-fat diet-induced metabolic damage. Proc. Natl. Acad. Sci. U. S .A., 2008, 105 (28), 9793-9798. (Pubitemid 352031379)
53. Cheng, H.L.; Mostoslavsky, R.; Saito, S.; Manis, J.P.; Gu, Y.; Patel, P.; Bronson, R.; Appella, E.; Alt, F.W.; Chua, K.F. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. U.S.A., 2003, 100 (19), 10794-10799. (Pubitemid 37140107)
54. Vakhrusheva, O.; Smolka, C.; Gajawada, P.; Kostin, S.; Boettger, T.; Kubin, T.; Braun, T.; Bober, E. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ. Res., 2008, 102 (6), 703-710. (Pubitemid 351457857)
55. Kubota, S.; Kurihara, T.; Mochimaru, H.; Satofuka, S.; Noda, K.; Ozawa, Y.; Oike, Y.; Ishida, S.; Tsubota, K. Prevention of ocular inflammation in endotoxin-induced uveitis with resveratrol by inhibiting oxidative damage and nuclear factor-kappaB activation. Invest. Ophthalmol. Vis. Sci, 2009, 50 (7), 3512-3519.
56. Sequeira, J.; Boily, G.; Bazinet, S.; Saliba, S.; He, X.; Jardine, K.; Kennedy, C.; Staines, W.; Rousseaux, C.; Mueller, R.; McBurney, M.W. sirt1-null mice develop an autoimmune-like condition. Exp. Cell Res., 2008, 314 (16), 3069-3074.
57. Lee, J.H.; Song, M.Y.; Song, E.K.; Kim, E.K.; Moon, W.S.; Han, M.K.; Park, J.W.; Kwon, K.B.; Park, B.H. Overexpression of SIRT1 protects pancreatic beta-cells against cytokine toxicity by suppressing the nuclear factor-kappaB signaling pathway. Diabetes, 2009, 58 (2), 344-351.
58. Schug, T.T.; Xu, Q.; Gao, H.; Peres-da-Silva, A.; Draper, D.W.; Fessler, M.B.; Purushotham, A.; Li, X. Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress. Mol. Cell Biol., 2010, 30 (19), 4712-4721.
59. Yang, Z.; Kahn, B.B.; Shi, H.; Xue, B.Z. Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1. J. Biol. Chem., 2010, 285 (25), 19051-19059.
60. Nerurkar, P.V.; Johns, L.M.; Buesa, L.M.; Kipyakwai, G.; Volper, E.; Sato, R.; Shah, P.; Feher, D.; Williams, P.G.; Nerurkar, V.R. Momordicacharantia (bitter melon) attenuates high-fat diet-associated oxidative stress and neuroinflammation. J. Neuroinflammation, 2011, 8, 64.
61. Singh, U.P.; Singh, N.P.; Singh, B.; Hofseth, L.J.; Price, R.L.; Nagarkatti, M.; Nagarkatti, P.S. Resveratrol (trans-3,5,4'-trihydroxystilbene) induces silent mating type information regulation-1 and down-regulates nuclear transcription factor-kappaB activation to abrogate dextran sulfate sodiuminduced colitis. J. Pharmacol. Exp. Ther., 2010, 332 (3), 829-839.
62. Csiszar, A.; Labinskyy, N.; Podlutsky, A.; Kaminski, P.M.; Wolin, M.S.; Zhang, C.; Mukhopadhyay, P.; Pacher, P.; Hu, F.; de Cabo, R.; Ballabh, P.; Ungvari, Z. Vasoprotective effects of resveratrol and SIRT1: Attenuation of cigarette smoke-induced oxidative stress and proinflammatory phenotypic alterations. Am. J. Physiol. Heart Circ. Physiol., 2008, 294 (6), H2721-H2735.
63. Nakamaru, Y.; Vuppusetty, C.; Wada, H.; Milne, J.C.; Ito, M.; Rossios, C.; Elliot, M.; Hogg, J.; Kharitonov, S.; Goto, H.; Bemis, J.E.; Elliott, P.; Barnes, P.J.; Ito, K. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J., 2009, 23 (9), 2810-2819.
64. Caito, S.; Hwang, J.W.; Chung, S.; Yao, H.; Sundar, I.K.; Rahman, I. PARP-1 inhibition does not restore oxidant-mediated reduction in SIRT1 activity. Biochem. Biophys. Res. Commun., 2010, 392 (3), 264-270.
65. Rajamohan, S.B.; Pillai, V.B.; Gupta, M.; Sundaresan, N.R.; Birukov, K.G.; Samant, S.; Hottiger, M.O.; Gupta, M.P. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol. Cell Biol., 2009, 29 (15), 4116-4129.
66. Rajendrasozhan, S.; Yang, S.R.; Kinnula, V.L.; Rahman, I. SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2008, 177 (8), 861-870. (Pubitemid 351600664)
67. Lee, M.; Kim, S.; Kwon, O.K.; Oh, S.R.; Lee, H.K.; Ahn, K. Antiinflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma. Int. Immunopharmacol., 2009, 9 (4), 418-424.
68. Kim, S.R.; Lee, K.S.; Park, S.J.; Min, K.H.; Choe, Y.H.; Moon, H.; Yoo, W.H.; Chae, H.J.; Han, M.K.; Lee, Y.C. Involvement of sirtuin 1 in airway inflammation and hyperresponsiveness of allergic airway disease. J. Allergy Clin. Immunol., 2010, 125 (2), 449-460.
69. Kwon, H.S.; Brent, M.M.; Getachew, R.; Jayakumar, P.; Chen, L.F.; Schnolzer, M.; McBurney, M.W.; Marmorstein, R.; Greene, W.C.; Ott, M. Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe, 2008, 3 (3), 158-167. (Pubitemid 351325758)
70. Kawahara, T.L.; Michishita, E.; Adler, A.S.; Damian, M.; Berber, E.; Lin, M.; McCord, R.A.; Ongaigui, K.C.; Boxer, L.D.; Chang, H.Y.; Chua, K.F. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell, 2009, 136 (1), 62-74.
71. Van Gool, F.; Gallí, M.; Gueydan, C.; Kruys, V.; Prevot, P.P.; Bedalov, A.; Mostoslavsky, R.; Alt, F.W.; De Smedt, T.; Leo, O. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat. Med., 2009, 15 (2), 206-210.
72. Bruzzone, S.; Fruscione, F.; Morando, S.; Ferrando, T.; Poggi, A.; Garuti, A.; D'Urso, A.; Selmo, M.; Benvenuto, F.; Cea, M.; Zoppoli, G.; Moran, E.; Soncini, D.; Ballestrero, A.; Sordat, B.; Patrone, F.; Mostoslavsky, R.; Uccelli, A.; Nencioni, A. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS. One, 2009, 4 (11), e7897.
73. Peng, S.L. Immune regulation by Foxo transcription factors. Autoimmunity, 2007, 40 (6), 462-469. (Pubitemid 47343358)
74. Wang, F.; Chan, C.H.; Chen, K.; Guan, X.; Lin, H.K.; Tong, Q. Deacetylation of FOXO3 by SIRT1 or SIRT2 leads to Skp2-mediated FOXO3 ubiquitination and degradation. Oncogene, 2011, doi: 10.1038/onc.2011.347.
75. Lin, L.; Hron, J.D.; Peng, S.L. Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. Immunity, 2004, 21 (2), 203-213. (Pubitemid 39094050)
76. van Loosdregt, J.; Vercoulen, Y.; Guichelaar, T.; Gent, Y.Y.; Beekman, J.M.; van Beekum, O.; Brenkman, A.B.; Hijnen, D.J.; Mutis, T.; Kalkhoven, E.; Prakken, B.J.; Coffer, P.J. Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization. Blood, 2010, 115 (5), 965-974.
77. van Loosdregt, J.; Brunen, D.; Fleskens, V.; Pals, C.E.; Lam, E.W.; Coffer, P.J. Rapid temporal control of Foxp3 protein degradation by sirtuin-1. PLoS. One, 2011, 6(4), e19047.
78. Gao, Z.; Ye, J. Inhibition of transcriptional activity of c-JUN by SIRT1. Biochem. Biophys. Res. Commun., 2008, 376 (4), 793-796.
79. Zhang, J.; Lee, S.M.; Shannon, S.; Gao, B.; Chen, W.; Chen, A.; Divekar, R.; McBurney, M.W.; Braley-Mullen, H.; Zaghouani, H.; Fang, D. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J. Clin. Invest., 2009, 119 (10), 3048-5308.
80. Zhang, R.; Chen, H.Z.; Liu, J.J.; Jia, Y.Y.; Zhang, Z.Q.; Yang, R.F.; Zhang, Y.; Xu, J.; Wei, Y.S.; Liu, D.P.; Liang, C.C. SIRT1 suppresses activator protein-1 transcriptional activity and cyclooxygenase-2 expression in macrophages. J. Biol. Chem., 2010, 285 (10), 7097-7110.
81. Nie, Y.; Erion, D.M.; Yuan, Z.; Dietrich, M.; Shulman, G.I.; Horvath, T.L.; Gao, Q. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nat. Cell Biol. , 2009, 11 (4), 492-500.
82. Sestito, R.; Madonna, S.; Scarponi, C.; Cianfarani, F.; Failla, C.M.; Cavani, A.; Girolomoni, G.; Albanesi, C. STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. FASEB J., 2011, 25 (3), 916-927.
83. Skokowa, J.; Lan, D.; Thakur, B.K.; Wang, F.; Gupta, K.; Cario, G.; Brechlin, A.M.; Schambach, A.; Hinrichsen, L.; Meyer, G.; Gaeste,l M.; Stanulla, M.; Tong, Q.; Welte, K. NAMPT is essential for the G-CSFinduced myeloid differentiation via a NAD(+)-sirtuin-1-dependent pathway. Nat. Med., 2009, 15 (2), 151-158.
84. Alcendor, R.R.; Gao, S.; Zhai, P.; Zablocki, D.; Holle, E.; Yu, X.; Tian, B.; Wagner, T.; Vatner, S.F.; Sadoshima, J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res., 2007, 100 (10), 1512-1521. (Pubitemid 46834764)
85. Zhang, Q.J.; Wang, Z.; Chen, H.Z.; Zhou, S.; Zheng, W.; Liu, G.; Wei, Y.S.; Cai, H.; Liu, D.P.; Liang, C.C. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc. Res., 2008, 80 (2), 191-199.
86. Ota, H.; Eto, M.; Ogawa, S.; Iijima, K.; Akishita, M.; Ouchi, Y. SIRT1/eNOS axis as a potential target against vascular senescence, dysfunction and atherosclerosis. J. Atheroscler. Thromb., 2010, 17(5), 431-435.
87. Borradaile, N.M.; Pickering, J.G. NAD(+), sirtuins, and cardiovascular disease. Curr. Pharm. Des., 2009, 15 (1), 110-117.
88. Sundaresan, N.R.; Samant, S.A.; Pillai, V.B.; Rajamohan, S.B.; Gupta, M.P. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol. Cell Biol., 2008, 28 (20), 6384-6401.
89. Tanno, M.; Kuno, A.; Yano, T.; Miura, T.; Hisahara, S.; Ishikawa, S.; Shimamoto, K.; Horio, Y. Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J. Biol. Chem., 2010, 285 (11), 8375-8382.
90. Sundaresan, N.R.; Pillai, V.B.; Gupta, M.P. Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy. J. Mol. Cell Cardiol., 2011, 51 (4), 614-618.
91. Sundaresan, N.R.; Gupta, M.; Kim, G.; Rajamohan, S.B.; Isbatan, A.; Gupta, M.P. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3adependent antioxidant defense mechanisms in mice. J. Clin. Invest., 2009, 119 (9), 2758-2771.
92. Stein, S.; Matter, C.M. Protective roles of SIRT1 in atherosclerosis. Cell Cycle, 2011, 10 (4), 640-647.
93. Cardellini, M.; Menghini, R.; Martelli, E.; Casagrande, V.; Marino, A.; Rizza, S.; Porzio, O.; Mauriello, A.; Solini, A.; Ippoliti, A.; Lauro, R.; Folli, F.; Federici, M. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1. Diabetes, 2009, 58 (10), 2396-2401.
94. Ghiso, J.; Frangione, B. Amyloidosis and Alzheimer's disease. Adv. Drug Deliv. Rev., 2002, 54 (12), 1539-1551. (Pubitemid 35346828)
95. Reddy, P.H.; McWeeney, S. Mapping cellular transcriptosomes in autopsied Alzheimer's disease subjects and relevant animal models. Neurobiol. Aging, 2006, 27 (8), 1060-1077. (Pubitemid 43850649)
96. Lustbader, J.W.; Cirilli, M.; Lin, C.; Xu, H.W.; Takuma, K.; Wang, N.; Caspersen, C.; Chen, X.; Pollak, S.; Chaney, M.; Trinchese, F.; Liu, S.; Gunn-Moore, F.; Lue, L.F.; Walker, D.G.; Kuppusamy, P.; Zewier, Z.L.; Arancio, O.; Stern, D.; Yan, S.S.; Wu, H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science, 2004, 304 (5669), 448-452. (Pubitemid 38495942)
97. Reddy, P.H.; Beal, M.F. Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res. Brain Res. Rev., 2005, 49 (3), 618-632. (Pubitemid 41546661)
98. Bonelli, R.M.; Hofmann, P. A review of the treatment options for Huntington's disease. Expert. Opin. Pharmacother., 2004, 5 (4), 767-776. (Pubitemid 38489502)
99. Musaro, A. State of the art and the dark side of amyotrophic lateral sclerosis.World J. Biol. Chem., 2010, 1 (5), 62-68.
100. Park, G.; Jeong, J.W.; Kim, J.E. SIRT1 deficiency attenuates MPP+-induced apoptosis in dopaminergic cells. FEBS Lett, 2011, 585 (1), 219-224.
101. Araki, T.; Sasaki, Y.; Milbrandt, J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science, 2004, 305 (5686), 1010-1013. (Pubitemid 39071777)
102. Parker, J.A.; Arango, M.; Abderrahmane, S.; Lambert, E.; Tourette, C.; Catoire, H.; Neri, C. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet., 2005, 37 (4), 349-350.
103. Qin, W.; Yang, T.; Ho, L.; Zhao, Z.; Wang, J.; Chen, L.; Zhao, W.; Thiyagarajan, M.; MacGrogan, D.; Rodgers, J.T.; Puigserver, P.; Sadoshima, J.; Deng, H.; Pedrini, S.; Gandy, S.; Sauve, A.A.; Pasinetti, G.M. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem., 2006, 281 (31), 21745-21754. (Pubitemid 44181878)
104. Kim, D.; Nguyen, M.D.; Dobbin, M.M.; Fischer, A.; Sananbenesi, F.; Rodgers, J.T.; Delalle, I.; Baur, J.A.; Sui, G.; Armour, S.M.; Puigserver, P.; Sinclair, D.A.; Tsai, L.H. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J., 2007, 26 (13), 3169-3179. (Pubitemid 47057498)
105. Pfister, J.A.; Ma, C.; Morrison, B.E.; D'Mello, S.R. Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS. One, 2008, 3 (12), e4090.
106. Lu, K.T.; Ko M.C.; Chen B.Y.; Huang J.C.; Hsieh C.W.; Lee M.C.; Chiou R.Y.; Wung B.S.; Peng C.H.; Yang, Y.L. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J. Agric. Food Chem., 2008, 56 (16), 6910-6913.
107. Chen, W.Y.; Wang, D.H.; Yen, R.C.; Luo, J.; Gu, W.; Baylin, S.B. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNAdamage responses. Cell, 2005, 123 (3), 437-448. (Pubitemid 41546674)
108. Sinclair, D. Sirtuins for healthy neurons. Nat. Genet., 2005, 37 (4), 339-340.
109. Wang, J.; Zhai, Q.; Chen, Y.; Lin, E.; Gu, W.; McBurney, M.W.; He, Z. A local mechanism mediates NAD-dependent protection of axon degeneration. J. Cell Biol., 2005, 170 (3), 349-355. (Pubitemid 41126935)
110. Prusiner, S.B.; Scott, M.R.; DeArmond, S.J.; Cohen, F.E. Prion protein biology. Cell, 1998, 93 (3), 337-348. (Pubitemid 28232079)
111. Aguzzi, A. Prion biology: The quest for the test. Nat. Methods., 2007, 4 (8), 614-616. (Pubitemid 47202469)
112. Chen, D.; Bruno, J.; Easlon, E.; Lin, S.J.; Cheng, H.L.; Alt, F.W.; Guarente, L. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev., 2008, 22 (13), 1753-1757. (Pubitemid 351915500)
113. Suzuki, K.; Koike, T. Mammalian Sir2-related protein (SIRT) 2-mediated modulation of resistance to axonal degeneration in slow Wallerian degeneration mice: A crucial role of tubulin deacetylation. Neuroscience, 2007, 147 (3), 599-612. (Pubitemid 46990654)
114. Outeiro, T.F.; Kontopoulos, E.; Altmann, S.M.; Kufareva, I.; Strathearn, K.E.; Amore, A.M.; Volk, C.B.; Maxwell, M.M.; Rochet, J.C.; McLean, P.J.; Young, A.B.; Abagyan, R.; Feany, M.B.; Hyman, B.T.; Kazantsev, A.G. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science, 2007, 317 (5837), 516-519. (Pubitemid 47196116)
115. Li, W.; Zhang, B.; Tang, J.; Cao, Q.; Wu, Y.; Wu, C.; Guo, J.; Ling, E.A.; Liang, F. Sirtuin 2, a mammalian homolog of yeast silent information regulator-2 longevity regulator, is an oligodendroglial protein that decelerates cell differentiation through deacetylating alpha-tubulin. J. Neurosci., 2007, 27 (10), 2606-2616. (Pubitemid 46393594)
116. Lappe-Siefke, C.; Goebbels, S.; Gravel, M.; Nicksch, E.; Lee, J.; Braun, P.E.; Griffiths, I.R.; Nave, K.A. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat. Genet., 2003, 33 (3), 366-374. (Pubitemid 36278853)
117. Rasband, M.N.; Tayler, J.; Kaga, Y.; Yang, Y.; Lappe-Siefke, C.; Nave, K.A.; Bansal, R. CNP is required for maintenance of axon-glia interactions at nodes of Ranvier in the CNS. Glia, 2005, 50 (1), 86-90. (Pubitemid 40516823)
118. Bifulco, M.; Laezza, C.; Stingo, S.; Wolff, J. 2',3'-Cyclic nucleotide 3'-phosphodiesterase: A membrane-bound, microtubule-associated protein and membrane anchor for tubulin. Proc. Natl. Acad. Sci. U. S. A., 2002, 99 (4), 1807-1812. (Pubitemid 34168971)
119. Lee, J.; Gravel, M.; Zhang, R.; Thibault, P.; Braun, P.E. Process outgrowth in oligodendrocytes is mediated by CNP, a novel microtubule assembly myelin protein. J. Cell Biol., 2005, 170 (4), 661-673. (Pubitemid 41186940)
120. Werner, H.B.; Kuhlmann, K.; Shen, S.; Uecker, M.; Schardt, A.; Dimova, K.; Orfaniotou, F.; Dhaunchak, A.; Brinkmann, B.G.; Mobius, W.; Guarente, L.; Casaccia-Bonnefil, P.; Jahn, O.; Nave, K.A. Proteolipid protein is required for transport of sirtuin 2 into CNS myelin. J. Neurosci., 2007, 27 (29), 7717-7730. (Pubitemid 47093807)
121. Kim, S.H.; Lu, H.F.; Alano, C.C. Neuronal Sirt3 protects against excitotoxic injury in mouse cortical neuron culture. PLoS. One, 2008, 6 (3), e14731.
122. Bosch-Presegue, L.; Vaquero, A. The Dual Role of Sirtuins in Cancer. Genes Cancer, 2011, 2 (6), 648-662.
123. Deng, C.X. SIRT1, is it a tumor promoter or tumor suppressor? Int. J. Biol . Sci., 2009, 5 (2), 147-152.
124. Cohen, H.Y.; Miller, C.; Bitterman, K.J.; Wall, N.R.; Hekking, B.; Kessler, B.; Howitz, K.T.; Gorospe, M.; de Cabo, R.; Sinclair, D.A. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science, 2004, 305 (5682), 390-392. (Pubitemid 38938153)
125. Vaziri, H.; Dessain, S.K.; Ng Eaton, E.; Imai, S.I.; Frye, R.A.; Pandita, T.K.; Guarente, L.; Weinberg, R.A. hSIR2(SIRT1) functions as an NADdependent p53 deacetylase. Cell, 2001, 107 (2), 149-159. (Pubitemid 33035942)
126. Giannakou, M.E.; Partridge, L. The interaction between FOXO and SIRT1: Tipping the balance towards survival. Trends Cell Biol., 2004, 14 (8), 408-412. (Pubitemid 39092697)
127. Yamakuchi, M.; Lowenstein, C.J. MiR-34, SIRT1 and p53: The feedback loop. Cell Cycle, 2009, 8 (59), 712-715.
128. Luo, J.; Nikolaev, A.Y.; Imai, S.; Chen, D.; Su, F.; Shiloh, A.; Guarente, L.; Gu, W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell, 2001, 107 (2), 137-148. (Pubitemid 33035941)
129. Langley, E.; Pearson, M.; Faretta, M.; Bauer, U.M.; Frye, R.A.; Minucci, S.; Pelicci, P.G.; Kouzarides, T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J., 2002, 21 (10), 2383-2396. (Pubitemid 34546711)
130. Fu, M.; Liu, M.; Sauve, A.A.; Jiao, X.; Zhang, X.; Wu, X.; Powell, M.J.; Yang, T.; Gu, W.; Avantaggiati, M.L.; Pattabiraman, N.; Pestell, T.G.; Wang, F.; Quong, A.A.; Wang, C.; Pestell, R.G. Hormonal control of androgen receptor function through SIRT1. Mol. Cell Biol., 2006, 26 (21), 8122-8135. (Pubitemid 44631010)
131. Ford, J.; Jiang, M.; Milner, J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res, 2005, 65 (22), 10457-10463. (Pubitemid 41743740)
132. Firestein, R.; Blander, G.; Michan, S.; Oberdoerffer, P.; Ogino, S.; Campbell, J.; Bhimavarapu, A.; Luikenhuis, S.; de Cabo, R.; Fuchs, C.; Hahn, W.C.; Guarente, L.P.; Sinclair, D.A. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS. One, 2008, 3 (4), e2020.
133. Brunet, A.; Sweeney, L.B.; Sturgill, J.F.; Chua, K.F.; Greer, P.L.; Lin, Y.; Tran, H.; Ross, S.E.; Mostoslavsky, R.; Cohen, H.Y.; Hu, L.S.; Cheng, H.L.; Jedrychowski, M.P.; Gygi, S.P.; Sinclair, D.A.; Alt, F.W.; Greenberg, M.E. 2004, Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science, 2004, 303 (5666), 2011-2015. (Pubitemid 38393275)
134. van der Horst, A.; Tertoolen, L.G.; de Vries-Smits, L.M.; Frye, R.A.; Medema, R.H.; Burgering, B.M. FOXO4 is acetylated upon peroxide stress and deacetylated by the longevity protein hSir2(SIRT1). J. Biol. Chem., 2004, 279 (28), 28873-28879. (Pubitemid 38915754)
135. Sawada, M.; Hayes, P.; Matsuyama, S. Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat. Cell Biol., 2003, 5 (4), 352-357. (Pubitemid 36432301)
136. Kume, S.; Haneda, M.; Kanasaki, K.; Sugimoto, T.; Araki, S.; Isshiki, K.; Isono, M.; Uzu, T.; Guarente, L.; Kashiwagi, A.; Koya, D. SIRT1 inhibits transforming growth factor beta-induced apoptosis in glomerular mesangial cells via Smad7 deacetylation. J. Biol. Chem., 2007, 282 (1), 151-158. (Pubitemid 47076643)
137. Wang, R.H.; Zheng, Y.; Kim, H.S.; Xu, X.; Cao, L.; Luhasen, T.; Lee, M.H.; Xiao, C.; Vassilopoulos, A.; Chen, W.; Gardner, K.; Man, Y.G.; Hung, M.C.; Finkel, T.; Deng, C.X. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol. Cell, 2008, 32 (1), 11-20.
138. Potente, M.; Ghaeni, L.; Baldessari, D.; Mostoslavsky, R.; Rossig, L.; Dequiedt, F.; Haendeler, J.; Mione, M.; Dejana, E.; Alt, F.W.; Zeiher, A.M.; Dimmeler, S. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev., 2007, 21 (20), 2644-2658. (Pubitemid 47607673)
139. Morselli, E.; Maiuri, M.C.; Markaki, M.; Megalou, E.; Pasparaki, A.; Palikaras, K.; Criollo, A.; Galluzzi, L.; Malik, S.A.; Vitale, I.; Michaud, M.; Madeo, F.; Tavernarakis, N.; Kroemer, G. Caloric restriction and resveratrol promote longevity through the Sirtuin-1-dependent induction of autophagy. Cell Death Dis., 2010, 1, e10.
140. Ford, J.; Ahmed, S.; Allison, S.; Jiang, M.; Milner, J. JNK2-dependent regulation of SIRT1 protein stability. Cell Cycle, 2008, 7 (19), 3091-3097.
141. Bourguignon, L.Y.; Xia, W.; Wong, G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J. Biol. Chem., 2009, 284 (5), 2657-2671.
142. Narala, S.R.; Allsopp, R.C.; Wells, T.B.; Zhang, G.; Prasad, P.; Coussens, M.J.; Rossi, D.J.; Weissman, I.L.; Vaziri, H. SIRT1 acts as a nutrientsensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. Mol. Biol. Cell, 2008, 19 (3), 1210-1219. (Pubitemid 351481832)
143. Wang, R.H.; Sengupta, K.; Li, C.; Kim, H.S.; Cao, L.; Xiao, C.; Kim, S.; Xu, X.; Zheng, Y.; Chilton, B.; Jia, R.; Zheng, Z.M.; Appella, E.; Wang, X.W.; Ried, T.; Deng, C.X. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell, 2008, 14 (4), 312-323.
144. Bradbury, C.A.; Khanim, F.L.; Hayden, R.; Bunce, C.M.; White, D.A.; Drayson, M.T.; Craddock, C.; Turner, B.M. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia, 2005, 19 (10), 1751-1759. (Pubitemid 41486152)
145. Huffman, D.M.; Grizzle, W.E.; Bamman, M.M.; Kim, J.S.; Eltoum, I.A.; Elgavish, A.; Nagy, T.R. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res., 2007, 67 (14), 6612-6618. (Pubitemid 47105506)
146. Stünkel, W.; Peh, B.K.; Tan, Y.C.; Nayagam, V.M.; Wang, X.; Salto-Tellez, M.; Ni, B.; Entzeroth, M.; Wood, J. Function of the SIRT1 protein deacetylase in cancer. Biotechnol. J., 2007, 2 (11), 1360-1368. (Pubitemid 350176266)
147. Hida, Y.; Kubo, Y.; Murao, K.; Arase, S. Strong expression of a longevityrelated protein, SIRT1, in Bowen's disease. Arch. Dermatol. Res., 2007, 299 (2), 103-106. (Pubitemid 46669407)
148. Liu, G.; Yuan, X.; Zeng, Z.; Tunici, P.; Ng, H.; Abdulkadir, I.R.; Lu, L.; Irvin, D.; Black, K.L.; Yu, J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer, 2006, 5, 67.
149. Liu, T.; Liu, P.Y.; Marshall, G.M. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res., 2009, 69 (5), 1702-1705.
150. North, B.J.; Verdin, E. Mitotic regulation of SIRT2 by cyclin-dependent kinase 1-dependent phosphorylation. J. Biol. Chem., 2007, 282 (27), 19546-19555. (Pubitemid 47100062)
151. Inoue, T.; Nakayama, Y.; Yamada, H.; Li, Y.C.; Yamaguchi, S.; Osaki, M.; Kurimasa, A.; Hiratsuka, M.; Katoh, M.; Oshimura, M. SIRT2 downregulation confers resistance to microtubule inhibitors by prolonging chronic mitotic arrest. Cell Cycle, 2009, 8 (8), 1279-1291.
152. Hiratsuka, M.; Inoue, T.; Toda, T.; Kimura, N.; Shirayoshi, Y.; Kamitani, H.; Watanabe, T.; Ohama, E.; Tahimic, C.G.; Kurimasa, A.; Oshimura, M. Proteomics-based identification of differentially expressed genes in human gliomas: Down-regulation of SIRT2 gene. Biochem. Biophys. Res. Commun., 2003, 309 (3), 558-566. (Pubitemid 37083288)
153. Das, C.; Lucia, M.S.; Hansen, K.C.; Tyler, J.K. CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature, 2009, 459 (7243), 113-117.
154. Alhazzazi, T.Y.; Kamarajan, P.; Joo, N.; Huang, J.Y.; Verdin, E.; D'Silva, N.J.; Kapila, Y.L. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer, 2011, 117 (8), 1670-1678.
155. Ashraf, N.; Zino, S.; Macintyre, A.; Kingsmore, D.; Payne, A.P.; George, W.D.; Shiels, P.G. Altered sirtuin expression is associated with node-positive breast cancer. Br. J. Cancer, 2006, 95 (8), 1056-1061. (Pubitemid 44606833)
156. Frye, R. "SIRT8" expressed in thyroid cancer is actually SIRT7. Br. J. Cancer, 2002, 87 (12), 1479. (Pubitemid 36044326)
157. De Nigris, F.; Cerutti, J.; Morelli, C.; Califano, D.; Chiariotti, L.; Viglietto, G.; Santelli, G.; Fusco, A. Isolation of a SIR-like gene, SIR-T8, that is overexpressed in thyroid carcinoma cell lines and tissues. Br. J. Cancer, 2002, 87 (12), 1479.
158. Finley, L.W.; Carracedo, A.; Lee, J.; Souza, A.; Egia, A.; Zhang, J.; Teruya-Feldstein, J.; Moreira, P.I.; Cardoso, S.M.; Clish, C.B.; Pandolfi, P.P.; Haigis, M.C. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell, 2011, 19 (3), 416-428.
159. Bell, E.L.; Emerling, B.M.; Ricoult, S.J.; Guarente, L. SirT3 suppresses hypoxia inducible factor 1alpha and tumor growth by inhibiting mitochondrial ROS production. Oncogene, 2011, 30 (26), 2986-2996.
160. Li, S.; Banck, M.; Mujtaba, S.; Zhou, M.M.; Sugrue, M.M.; Walsh, M.J. p53-induced growth arrest is regulated by the mitochondrial SirT3 deacetylase. PLoS. One, 2010, 5 (5), e10486.
161. Zhao, W.; Kruse, J.P.; Tang, Y.; Jung, S.Y.; Qin, J.; Gu, W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature, 2008, 451 (7178), 587-590. (Pubitemid 351186268)
162. Brooks, C.L.; Gu, W. p53 Activation: A case against Sir. Cancer Cell, 2008, 13 (5), 377-378. (Pubitemid 351609448)
163. Lara, E.; Mai, A.; Calvanese, V.; Altucci, L.; Lopez-Nieva, P.; Martinez-Chantar, M.L.; Varela-Rey, M.; Rotili, D.; Nebbioso, A.; Ropero, S.; Montoya, G.; Oyarzabal, J.; Velasco, S.; Serrano, M.; Witt, M.; Villar-Garea, A.; Imhof, A.; Mato, J.M.; Esteller, M.; Fraga, M.F. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene, 2009, 28 (6), 781-791.
164. Vijg, J.; Maslov, A.Y.; Suh, Y. Aging: A sirtuin shake-up? Cell, 2008, 135 (5), 797-798.
165. Wang, C.; Chen, L.; Hou, X.; Li, Z.; Kabra, N.; Ma, Y.; Nemoto, S.; Finkel, T.; Gu, W.; Cress, W.D.; Chen, J. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat. Cell Biol., 2006, 8 (9), 1025-1031. (Pubitemid 44314735)
166. Yuan, J.; Minter-Dykhouse, K.; Lou, Z. A c-Myc-SIRT1 feedback loop regulates cell growth and transformation. J. Cell Biol., 2009, 185 (2), 203-211.
167. Iwahara, N.; Hisahara, S.; Hayashi, T.; Horio, Y. Transcriptional activation of NAD+-dependent protein deacetylase SIRT1 by nuclear receptor TLX. Biochem. Biophys. Res. Commun., 2009, 386 (4), 671-675.
168. Lain, S.; Hollick, J.J.; Campbell, J.; Staples, O.D.; Higgins, M.; Aoubala, M.; McCarthy, A.; Appleyard, V.; Murray, K.E.; Baker, L.; Thompson, A.; Mathers, J.; Holland, S.J.; Stark, M.J.; Pass, G.; Woods, J.; Lane, D.P.; Westwood, N.J. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell, 2008, 13 (5), 454-463. (Pubitemid 351609441)
169. Calin, G.A.; Sevignani, C.; Dumitru, C.D.; Hyslop, T.; Noch, E.; Yendamuri, S.; Shimizu, M.; Rattan, S.; Bullrich, F.; Negrini, M.; Croce, C.M. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U. S. A., 2004, 101 (9), 2999-3004. (Pubitemid 38327724)
170. Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A.; Downing, J.R.; Jacks, T.; Horvitz, H.R.; Golub, T.R. MicroRNA expression profiles classify human cancers. Nature, 2005, 435 (7043), 834-838. (Pubitemid 40839735)
171. He, L.; He, X.; Lowe, S.W.; Hannon, G.J. microRNAs join the p53 network-another piece in the tumor-suppression puzzle. Nat. Rev. Cancer, 2007, 7 (11), 819-822. (Pubitemid 350006254)
172. Yamakuchi, M.; Ferlito, M.; Lowenstein, C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. U.S.A., 2008, 105 (36), 13421-13426.
173. Daitoku, H.; Hatta, M.; Matsuzaki, H.; Aratani, S.; Ohshima, T.; Miyagishi, M.; Nakajima, T.; Fukamizu, A. Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity. Proc. Natl. Acad. Sci. U.S.A., 2004, 101 (27), 10042-10047. (Pubitemid 38891191)
174. Jung-Hynes, B.; Ahmad, N. Role of p53 in the anti-proliferative effects of Sirt1 inhibition in prostate cancer cells. Cell Cycle, 2009, 8 (10), 1478-1483.
175. Frescas, D.; Valenti, L.; Accili, D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J. Biol. Chem., 2005, 280 (21), 20589-20595. (Pubitemid 40776761)
176. Stankovic-Valentin, N.; Deltour, S.; Seeler, J.; Pinte, S.; Vergoten, G.; Guerardel, C.; Dejean, A.; Leprince, D. An acetylation/deacetylation- SUMOylation switch through a phylogenetically conserved psiKXEP motif in the tumor suppressor HIC1 regulates transcriptional repression activity. Mol. Cell Biol., 2007, 27 (7), 2661-2675. (Pubitemid 46581356)
177. Chen, W.Y.; Zeng, X.; Carter, M.G.; Morrell, C.N.; Chiu Yen, R.W.; Esteller, M.; Watkins, D.N.; Herman, J.G.; Mankowski, J.L.; Baylin, S.B. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat. Genet., 2003, 33(2), 197-202. (Pubitemid 36177074)
178. Abdelmohsen, K.; Pullmann, R., Jr.; Lal, A.; Kim, H.H.; Galban, S.; Yang, X.; Blethrow, J.D.; Walker, M.; Shubert, J.; Gillespie, D.A.; Furneaux, H.; Gorospe, M. Phosphorylation of HuR by Chk2 regulates SIRT1 expression. Mol. Cell, 2007, 25 (4), 543-557. (Pubitemid 46274441)
179. Kim, J.E.; Chen, J.; Lou, Z. DBC1 is a negative regulator of SIRT1. Nature, 2008, 451 (7178), 583-586. (Pubitemid 351186264)
180. McBurney, M.W.; Yang, X.; Jardine, K.; Bieman, M.; Th'ng, J.; Lemieux, M. The absence of SIR2alpha protein has no effect on global gene silencing in mouse embryonic stem cells. Mol. Cancer Res., 2003, 1 (5), 402-409. (Pubitemid 36437926)
181. Kamel, C.; Abrol, M.; Jardine, K.; He, X.; McBurney, M.W. SirT1 fails to affect p53-mediated biological functions. Aging Cell, 2006, 5 (1), 81-88. (Pubitemid 43348965)
182. Banks, A.S.; Kon, N.; Knight, C.; Matsumoto, M.; Gutierrez-Juarez, R.; Rossetti, L.; Gu, W.; Accili, D. SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab., 2008, 8 (4), 333-341.
183. Bereshchenko, O.R.; Gu, W.; Dalla-Favera, R. Acetylation inactivates the transcriptional repressor BCL6. Nat. Genet., 2002, 32 (4), 606-613. (Pubitemid 35435172)
184. Sun, Y.; Sun, D.; Li, F.; Tian, L.; Li, C.; Li, L.; Lin, R.; Wang, S. Downregulation of Sirt1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells. Lung Cancer, 2007, 58 (1), 21-29. (Pubitemid 47385929)
185. Wong, S.; Weber, J.D. Deacetylation of the retinoblastoma tumor suppressor protein by SIRT1. Biochem. J., 2007, 407 (3), 451-460. (Pubitemid 350058478)
186. Kabra, N.; Li, Z.; Chen, L.; Li, B.; Zhang, X.; Wang, C.; Yeatman, T.; Coppola, D.; Chen, J. SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J. Biol. Chem., 2009, 284 (27), 18210-18217.
187. Zaffaroni, N.; Pennati, M.; Daidone, M.G. Survivin as a target for new anticancer interventions. J. Cell Mol. Med., 2005, 9 (2), 360-372.
188. Boily, G.; He, X.H.; Pearce, B.; Jardine, K.; McBurney, M.W. SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene, 2009, 28 (32), 2882-2893.
189. Oberdoerffer, P.; Michan, S.; McVay, M.; Mostoslavsky, R.; Vann, J.; Park, S.K.; Hartlerode, A.; Stegmuller, J.; Hafner, A.; Loerch, P.; Wright, S.M.; Mills, K.D.; Bonni, A.; Yankner, B.A.; Scully, R.; Prolla, T.A.; Alt, F.W.; Sinclair, D.A. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell, 2008, 135 (5), 907-918.
190. Chua, K.F.; Mostoslavsky, R.; Lombard, D.B.; Pang, W.W.; Saito, S.; Franco, S.; Kaushal, D.; Cheng, H.L.; Fischer, M.R.; Stokes, N.; Murphy, M.M.; Appella, E.; Alt, F.W. Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab., 2005, 2 (1), 67-76. (Pubitemid 43239826)
191. Inoue, T.; Hiratsuka, M.; Osaki, M.; Oshimura, M. The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle, 2007, 6 (9), 1011-1018. (Pubitemid 46708571)
192. Inoue, T.; Hiratsuka, M.; Osaki, M.; Yamada, H.; Kishimoto, I.; Yamaguchi, S.; Nakano, S.; Katoh, M.; Ito, H.; Oshimura, M. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene, 2007, 26 (7), 945-957.
193. Vaquero, A.; Scher, M.B.; Lee, D.H.; Sutton, A.; Cheng, H.L.; Alt, F.W.; Serrano, L.; Sternglanz, R.; Reinberg, D. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev., 2006, 20 (10), 1256-1261. (Pubitemid 43727586)
194. Bae, N.S.; Swanson, M.J.; Vassilev, A.; Howard, B.H. Human histone deacetylase SIRT2 interacts with the homeobox transcription factor HOXA10. J. Biochem., 2004, 135 (6), 695-700. (Pubitemid 38899716)
195. Dryden, S.C.; Nahhas, F.A.; Nowak, J.E.; Goustin, A.S.; Tainsky, M.A. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol. Cell Biol., 2003, 23 (9), 3173-3185. (Pubitemid 36459231)
196. Lennerz, V.; Fatho, M.; Gentilini, C.; Frye, R.A.; Lifke, A.; Ferel, D.; Wolfel, C.; Huber, C.; Wolfel, T. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl. Acad. Sci. U.S.A., 2005, 102 (44), 16013-16018. (Pubitemid 41552859)
197. Pandithage, R.; Lilischkis, R.; Harting, K.; Wolf, A.; Jedamzik, B.; Luscher-Firzlaff, J.; Vervoorts, J.; Lasonder, E.; Kremmer, E.; Knoll, B.; Luscher, B. The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J. Cell Biol., 2008, 180 (5), 915-929. (Pubitemid 351398419)
198. Li, Y.; Matsumori, H.; Nakayama, Y.; Osaki, M.; Kojima, H.; Kurimasa, A.; Ito, H.; Mori, S.; Katoh, M.; Oshimura, M.; Inoue, T. SIRT2 downregulation in HeLa can induce p53 accumulation via p38 MAPK activationdependent p300 decrease, eventually leading to apoptosis. Genes Cells, 2011, 16 (1), 34-45.
199. Lanza, I.R.; Short, D.K.; Short, K.R.; Raghavakaimal, S.; Basu, R.; Joyner, M.J.; McConnell, J.P.; Nair, K.S. Endurance exercise as a countermeasure for aging. Diabetes, 2008, 57 (11), 2933-2942.
200. Kim, H.S.; Patel, K.; Muldoon-Jacobs, K.; Bisht, K.S.; Aykin-Burns, N.; Pennington, J.D.; van der Meer, R.; Nguyen, P.; Savage, J.; Owens, K.M.; Vassilopoulos, A.; Ozden, O.; Park, S.H.; Singh, K.K.; Abdulkadir, S.A.; Spitz, D.R.; Deng, C.X.; Gius, D. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell, 2010, 17 (1), 41-52.
201. Allison, S.J.; Milner, J. SIRT3 is pro-apoptotic and participates in distinct basal apoptotic pathways. Cell Cycle, 2007, 6 (21), 2669-2677. (Pubitemid 350224051)
202. Park, S.H.; Ozden, O.; Jiang, H.; Cha, Y.I.; Pennington, J.D.; Aykin-Burns, N.; Spitz, D.R.; Gius, D.; Kim, H.S. Sirt3, Mitochondrial ROS, Ageing, and Carcinogenesis. Int. J. Mol. Sci., 2011, 12 (9), 6226-6239.
203. Marfe, G.; Tafani, M.; Indelicato, M.; Sinibaldi-Salimei, P.; Reali, V.; Pucci, B.; Fini, M.; Russo, M.A. Kaempferol induces apoptosis in two different cell lines via Akt inactivation, Bax and SIRT3 activation, and mitochondrial dysfunction. J. Cell Biochem., 2009, 106 (4), 643-650.
204. Alhazzazi, T.Y.; Kamarajan, P.; Verdin, E.; Kapila, Y.L. SIRT3 and cancer: Tumor promoter or suppressor? Biochim. Biophys Acta, 2011, 1816 (1), 80-88.
205. Mahlknecht, U.; Ho, A.D.; Voelter-Mahlknecht, S. Chromosomal organization and fluorescence in situ hybridization of the human Sirtuin 6 gene. Int. J. Oncol., 2006, 28 (2), 447-456.
206. McGlynn, L.; Curle, J.; Edwards, J.; Shiels, P. Prognosis and response predictions-Pronostic factors and biomarkers-preclinical.Evaluating the role of sirtuins 5, 6 & 7in breast cancer. Cancer Res., 2009, (69), abstract nr 3032.
207. Michishita, E.; Park, J.Y.; Burneskis, J.M.; Barrett, J.C.; Horikawa, I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell, 2005, 16 (10), 4623-4635. (Pubitemid 41416446)
208. Voelter-Mahlknecht, S.; Letzel, S.; Mahlknecht, U. Fluorescence in situ hybridization and chromosomal organization of the human Sirtuin 7 gene. Int. J. Oncol., 2006, 28 (4), 899-908.
209. Howitz, K.T.; Bitterman, K.J.; Cohen, H.Y.; Lamming, D.W.; Lavu, S.; Wood, J.G.; Zipkin, R.E.; Chung, P.; Kisielewski, A.; Zhang, L.L.; Scherer, B.; Sinclair, D.A. Small molecule activators of Sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 2003, 425 (6954), 191-196. (Pubitemid 37150899)
210. Milne, J.C.; Denu, J.M. The Sirtuin family: Therapeutic targets to treat diseases of aging. Curr. Opin. Chem. Biol., 2008, 12 (1), 11-17.
211. Yang, H.; Baur, J.A.; Chen, A.; Miller, C.; Adams, J.K.; Kisielewski, A.; Howitz, K.T.; Zipkin, R.E.; Sinclair, D.A. Design and synthesis of compounds that extend yeast replicative lifespan. Aging Cell, 2007, 6 (1), 35-43. (Pubitemid 46140138)
212. Huber, K.; Superti-Furga, G. After the grape rush: Sirtuins as epigenetic drug targets in neurodegenerative disorders. Bioorg. Med. Chem., 2011, 19 (12), 3616-3624.
213. Kelly, G.S. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: Part 1. Altern. Med. Rev., 2010, 15 (3), 245-263.
214. Kelly, G.S. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: Part 2. Altern Med. Rev., 2010, 15 (4), 313-328.
215. Sadruddin, S.; Arora, R. Resveratrol: Biologic and therapeutic implications.J. Cardiometab. Syndr., 2009, 4 (2), 102-106.
216. Alcaín, F.J.; Villalba, J.M. Sirtuin activators. Expert.Opin.Ther. Pat., 2009, 19 (4), 403-414.
217. Marques, F.Z.; Markus, M.A.; Morris, B.J. Resveratrol: Cellular actions of a potent natural chemical that confers a diversity of health benefits. Int. J. Biochem. Cell Biol., 2009, 41 (11), 2125-2128.
218. Lee, S.M.; Yang, H.; Tartar, D.M.; Gao, B.; Luo, X.; Ye, S.Q.; Zaghouani, H.; Fang, D. Prevention and treatment of diabetes with resveratrol in a nonobese mouse model of type 1 diabetes. Diabetología, 2011, 54 (5), 1136-1146.
219. Sharma, S.; Misra, C.S.; Arumugam, S.; Roy, S.; Shah, V.; Davis, J.A.; Shirumalla, R.K.; Ray, A. Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes. Phytother. Res., 2011, 25 (1), 67-73.
220. Milne, J.C.; Lambert, P.D.; Schenk, S.; Carney, D.P.; Smith, J.J.; Gagne, D.J.; Jin, L.; Boss, O.; Perni, R.B.; Vu, C.B.; Bemis, J.E.; Xie, R.; Disch, J.S.; Ng, P.Y.; Nunes, J.J.; Lynch, A.V.; Yang, H.; Galones, H.; Israelian, K.; Choy, W.; Iffland, A.; Lavu, S.; Medvedik, O.; Sinclair, D.A.; Olefsky, J.M.; Jirousek, M.R.; Elliott, P.J.; Westphal, C.H. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature, 2007, 450 (7170), 712-716. (Pubitemid 350207685)
221. Sulaiman, M.; Matta, M.J.; Sunderesan, N.R.; Gupta, M.P.; Periasamy, M.; Gupta, M. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol., 2010, 298 (3), H833-843.
222. Orimo, M.; Minamino, T.; Miyauchi, H.; Tateno, K.; Okada, S.; Moriya, J.; Komuro, I. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler. Thromb. Vasc. Biol., 2009, 29 (6), 889-894.
223. Tikoo, K.; Singh, K.; Kabra, D.; Sharma, V.; Gaikwad, A. Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic. Res., 2008, 42 (4), 397-404.
224. Franco, J.G.; de Moura, E.G.; Koury, J.C.; Trotta, P.A.; Cordeiro, A.; Souza, L.L.; Almeida, N.A.; Lima Nda, S.; Pazos-Moura, C.C.; Lisboa, P.C.; Passos, M.C. Resveratrol reduces lipid peroxidation and increases sirtuin 1 expression in adult animals programmed by neonatal protein restriction. J. Endocrinol., 2010, 207 (3), 319-328.
225. Csiszar, A.; Labinskyy, N.; Pinto, J.T.; Ballabh, P.; Zhang, H.; Losonczy, G.; Pearson, K.; de Cabo, R.; Pacher, P.; Zhang, C.; Ungvari, Z. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am. J. Physiol. Heart Circ. Physiol., 2009, 297 (1), H13-20.
226. Ramadori, G.; Gautron, L.; Fujikawa, T.; Vianna, C.R.; Elmquist, J.K.; Coppari, R. Central administration of resveratrol improves diet-induced diabetes. Endocrinology, 2009, 150 (12), 5326-5333.
227. Smith, J.J.; Kenney, R.D.; Gagne, D.J.; Frushour, B.P.; Ladd, W.; Galonek, H.L.; Israelian, K.; Song, J.; Razvadauskaite, G.; Lynch, A.V.; Carney, D.P.; Johnson, R.J.; Lavu, S.; Iffland, A.; Elliott, P.J.; Lambert, P.D.; Elliston, K.O.; Jirousek, M.R.; Milne, J.C.; Boss, O. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Syst. Biol., 2009, 10, 3, 31.
228. Sun, C.; Zhang, F.; Ge, X.; Yan, T.; Chen, X.; Shi, X.; Zhai, Q. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab., 2007, 6 (4), 307-319. (Pubitemid 47468091)
229. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; Geny, B.; Laakso, M.; Puigserver, P.; Auwerx, J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 2006, 127 (6), 1109-1122. (Pubitemid 44894520)
230. Baur, J.A.; Pearson, K.J.; Price, N.L.; Jamieson, H.A.; Lerin, C.; Kalra, A.; Prabhu, V.V.; Allard, J.S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P.J.; Poosala, S.; Becker, K.G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K.W.; Spencer, R.G.; Lakatta, E.G.; Le Couteur, D.; Shaw, R.J.; Navas, P.; Puigserver, P.; Ingram, D.K.; de Cabo, R.; Sinclair, D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444 (7117), 337-342. (Pubitemid 44764104)
231. Zhang, C.; Feng, Y.; Qu, S.; Wei, X.; Zhu, H.; Luo, Q.; Liu, M.; Chen, G.; Xiao, X. Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc. Res., 2011, 90 (3), 538-545.
232. Ho, D.J.; Calingasan, N.Y.; Wille, E.; Dumont, M.; Beal, M.F. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp. Neurol., 2010, 225 (1), 74-84.
233. Xia, N.; Daiber, A.; Habermeier, A.; Closs, E.I.; Thum, T.; Spanier, G.; Lu, Q.; Oelze, M.; Torzewski, M.; Lackner, K.J.; Münzel, T.; Förstermann, U.; Li, H. Resveratrol reverses endothelial nitric-oxide synthase uncoupling in apolipoprotein E knockout mice. J. Pharmacol. Exp. Ther, 2010, 335 (1), 149-154.
234. Yoshida, Y.; Shioi, T.; Izumi, T. Resveratrol ameliorates experimental autoimmune myocarditis. Circ. J., 2007, 71 (3), 397-404. (Pubitemid 46409545)
235. Zhang, Z.; Lowry, S.F.; Guarente, L.; Haimovich, B. Roles of SIRT1 in the acute and restorative phases following induction of inflammation. J. Biol. Chem., 2010, 285 (53), 41391-41401.
236. Shindler, K.S.; Ventura, E.; Rex, T.S.; Elliott, P.; Rostami, A. SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest. Ophthalmol. Vis. Sci., 2007, 48(8), 3602-3609. (Pubitemid 351261095)
237. Della-Morte, D.; Dave, K.R.; Defazio, R.A.; Bao, Y.C.; Raval, A.P.; Perez-Pinzon, M.A. Resveratrol pretreatment protects rat brainfrom cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience, 2009, 159 (3), 993-1002.
238. Patel, K.R.; Scott, E.; Brown, V.A.; Gescher, A.J.; Steward, W.P.; Brown, K. Clinical trials of resveratrol. Ann. N. Y. Acad. Sci., 2011, 1215, 161-169.
239. Kennedy, D.O.; Wightman, E.L.; Reay, J.L.; Lietz, G.; Okello, E.J.; Wilde, A.; Haskell, C.F. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: A double-blind, placebo-controlled, crossover investigation. Am. J. Clin. Nutr., 2010, 91 (6), 1590-1597.
240. Nguyen, A.V.; Martinez, M.; Stamos, M.J.; Moyer, M.P.; Planutis, K.; Hope, C.; Holcombe, R.F. Results of a phase I pilot clinical trial examining the effect of plant-derived resveratrol and grape powder on Wnt pathway target gene expression in colonic mucosa and colon cancer. Cancer Manag. Res., 2009, 1, 25-37.
241. Brown, V.A.; Patel, K.R.; Viskaduraki, M.; Crowell, J.A.; Perloff, M.; Booth, T.D.; Vasilinin, G.; Sen, A.; Schinas, A.M.; Piccirilli, G.; Brown, K.; Steward, W.P.; Gescher, A.J.; Brenner, D.E. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: Safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res., 2010, 70 (22), 9003-9011.
242. Borra, M.T.; Smith, B.C.; Denu, J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem., 2005, 280 (17), 17187-17195. (Pubitemid 41389185)
243. Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; Westman, E.A.; Caldwell, S.D.; Napper, A.; Curtis, R.; DiStefano, P.S.; Fields, S.; Bedalov, A.; Kennedy, B.K. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem., 2005, 280 (17), 17038-17045. (Pubitemid 41389166)
244. Mouchiroud, L.; Molin, L.; Dallière, N.; Solari, F. Life span extension by resveratrol, rapamycin, and metformin: The promise of dietary restriction mimetics for an healthy aging. Biofactors, 2010, 36 (5), 377-382.
245. Kitada, M.; Kume, S.; Imaizumi, N.; Koya, D. Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes, 2011, 60 (2), 634-643.
246. Dasgupta, B.; Milbrandt, J. Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. U S A, 2007, 104 (17), 7217-7222. (Pubitemid 47186035)
247. Karuppagounder, S.S.; Pinto, J.T.; Xu, H.; Chen, H.L.; Beal, M.F.; Gibson, G.E. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem. Int., 2009, 54 (2), 111-118.
248. Beher, D.; Wu, J.; Cumine, S.; Kim, K.W.; Lu, S.C.; Atangan, L.; Wang, M. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des., 2009, 74 (6), 619-624.
249. Um, J.H.; Park, S.J.; Kang, H.; Yang, S.; Foretz, M.; McBurney, M.W.; Kim, M.K.; Viollet, B.; Chung, J.H. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes, 2010, 59 (3), 554-563.
250. Lin, J.N.; Lin, V.C.; Rau, K.M.; Shieh, P.C.; Kuo, D.H.; Shieh, J.C.; Chen, W.J.; Tsai, S.C.; Way, T.D. Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J. Agric. Food Chem., 2010, 58 (3), 1584-1592.
251. Park, J.M.; Kim, T.H.; Bae, J.S.; Kim, M.Y.; Kim, K.S.; Ahn, Y.H. Role of resveratrol in FOXO1-mediated gluconeogenic gene expression in the liver. Biochem. Biophys. Res. Commun., 2010, 403 (3-4), 329-334.
252. Feige, J.N.; Lagouge, M.; Canto, C.; Strehle, A.; Houten, S.M.; Milne, J.C.; Lambert, P.D.; Mataki C.; Elliott, P.J.; Auwerx, J. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab., 2008, 8 (5), 347-358.
253. Camins, A.; Sureda, F.X.; Junyent, F.; Verdaguer, E.; Folch, J.; Pelegri, C.; Vilaplana, J.; Beas-Zarate, C.; Pallàs, M. Sirtuin activators: Designing molecules to extend life span. Biochim. Biophys Acta, 2010, 1799 (10-12), 740-749.
254. Malik, R.; Kashyap, A.; Bansal, K.; Sharma, P.; Rayasam, G.V.; Davis, J.A.; Bora, RS.; Ray, A.; Saini, K.S. Comparative deacetylase activity of wild type and mutants of SIRT1. Biochem. Biophys Res. Commun., 2010, 391 (1), 739-743.
255. Walter, A.K.; Yang, F.; Jiang, K.; Ji, J.Y.; Watts, J.L.; Purushotham, A.; Boss, O.; Hirsch, M.L.; Ribich, S.; Smith, J.J.; Israelian, K.; Westphal, C.H.; Rodgers, J.T.; Shioda, T.; Elson, S.L.; Mulligan, P.; Najafi-Shoushtari, H.; Black, J.C.; Thakur, J.K.; Kadyk, L.C.; Whetstine, J.R.; Mostoslavsky, R.; Puigserver, P.; Li, X.; Dyson, N.J.; Hart, A.C.; Näär, A.M. Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev., 2010, 24 (13), 1403-1417.
256. Yamazaki, Y.; Usui, I.; Kanatani, Y.; Matsuya Y.; Tsuneyama, K.; Fujisaka, S.; Bukhari, A.; Suzuki, H.; Senda, S.; Imanishi, S.; Hirata, K.; Ishiki, M.; Hayashi, R.; Urakaze, M.; Nemoto, H.; Kobayashi, M.; Tobe, K. Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. Am. J. Physiol. Endocrinol. Metab., 2009, 297 (5), E1179-E1186.
257. He, W.; Wang, Y.; Zhang, M.Z.; You, L.; Davis, L.S.; Fan, H.; Yang, H.C.; Fogo, A.B.; Zent, R.; Harris, R.C.; Breyer, M.D.; Hao, C.M. Sirt1 activation protects the mouse renal medulla from oxidative injury. J. Clin. Invest., 2010, 120 (4), 1056-1068.
258. Pacholec, M.; Bleasdale, J.E.; Chrunyk, B.; Cunningham, D.; Flynn, D.; Garofalo, R.S.; Griffith, D.; Griffor, M.; Loulakis, P.; Pabst, B.; Qiu, X.; Stockman, B.; Thanabal, V.; Varghese, A.; Ward, J.; Withka, J.; Ahn, K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem., 2010, 285 (11), 8340-8351.
259. Dai, H.; Kustigian, L.; Carney, D.; Case, A.; Considine, T.; Hubbard, B.P.; Perni, R.B.; Riera, T.V.; Szczepankiewicz, B.; Vlasuk, G.P.; Stein, R.L. SIRT1 activation by small molecules: Kinetic and biophysical evidence for direct interaction of enzyme and activator. J. Biol. Chem., 2010, 285 (43), 32695-32703.
260. Huber, J.L.; McBurney, M.W.; Distefano, P.S.; McDonagh, T. SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183. Future Med. Chem., 2010, 2 (12), 1751-1759.
261. Nayagam, V.M.; Wang, X.; Tan, Y.C.; Poulsen, A.; Goh, K.C.; Ng, T.; Wang, H.; Song, H.Y.; Ni, B.; Entzeroth, M.; Stünkel, W. SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents. J. Biomol. Screen., 2006, 11 (8), 959-967. (Pubitemid 44847150)
262. Bemis, J.E.; Vu, C.B.; Xie, R.; Nunes, J.J.; Ng, P.Y.; Disch, J.S.; Milne, J.C.; Carney, D.P.; Lynch, A.V.; Jin, L.; Smith, J.J.; Lavu, S.; Iffland, A.; Jirousek, M.R.; Perni, R.B. Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators. Bioorg. Med. Chem. Lett., 2009, 19 (8), 2350-2353.
263. Vu, C.B.; Bemis, J.E.; Disch, J.S.; Ng, P.Y.; Nunes, J.J.; Milne, J.C.; Carney, D.P.; Lynch, A.V.; Smith, J.J.; Lavu, S.; Lambert, P.D.; Gagne, D.J.; Jirousek, M.R.; Schenk, S.; Olefsky, J.M.; Perni, R.B. Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators. J. Med. Chem., 2009, 52 (5), 1275-1283.
264. Mai, A.; Valente, S.; Meade, S.; Carafa, V.; Tardugno, M.; Nebbioso, A.; Galmozzi, A.; Mitro, N.; De Fabiani, E.; Altucci, L.; Kazantsev, A. Study of 1,4-dihydropyridine structural scaffold: Discovery of novel sirtuin activators and inhibitors. J. Med. Chem., 2009, 52 (17), 5496-5504.
265. Cen, Y. Sirtuins inhibitors: The approach to affinity and selectivity. Biochim. Biophys. Acta, 2010, 1804 (8), 1635-1644.
266. Lara, E.; Mai, A.; Calvanese, V.; Altucci, L.; Lopez-Nieva, P.; Martinez-Chantar, M.L.; Varela-Rey, M.; Rotili, D.; Nebbioso, A.; Ropero, S.; Montoya, G.; Oyarzabal, J.; Velasco, S.; Serrano, M.; Witt, M.; Villar-Garea, A.; Imhof, A.; Mato, J.M.; Esteller, M.; Fraga, M.F. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene, 2009, 28 (6), 781-791.
267. Avalos, J.L.; Bever, K.M.; Wolberger, C. Mechanism of sirtuin inhibition by nicotinamide: Altering the NAD(?) cosubstrate specificity of a Sir2 enzyme. Mol. Cel., 2005, 17 (6), 855-868. (Pubitemid 40386946)
268. Suzuki, T.; Imai, K.; Imai, E.; Iida, S.; Ueda, R.; Tsumoto, H.; Nakagawa, H.; Miyata, N. Design, synthesis, enzyme inhibition, and tumor cell growth inhibition of 2-anilinobenzamide derivatives as SIRT1 inhibitors. Bioorg. Med. Chem., 2009, 17 (16), 5900-5905.
269. Medda, F.; Russell, R.J.; Higgins, M.; McCarthy, A.R.; Campbell, J.; Slawin, A.M.; Lane, D.P.; Lain, S.; Westwood, N.J. Novel cambinol analogs as sirtuin inhibitors: Synthesis, biological evaluation, and rationalization of activity. J. Med. Chem., 2009, 52 (9), 2673-2682.
270. Pagans, S.; Pedal, A.; North, B.J.; Kaehlcke, K.; Marshall, B.L.; Dorr, A.; Hetzer-Egger, C.; Henklein, P.; Frye, R.; McBurney, M.W.; Hruby, H.; Jung, M.; Verdin, E.; Ott, M. SIRT1 regulates HIV transcription via Tat deacetylation. PLoS. Biol., 2005, 3 (2), e41.
271. Napper, A.D.; Hixon, J.; McDonagh, T.; Keavey, K.; Pons, J.F.; Barker, J.; Yau, W.T.; Amouzegh, P.; Flegg, A.; Hamelin, E.; Thomas, R.J.; Kates, M.; Jones, S.; Navia, M.A.; Saunders, J.O.; DiStefan,o P.S.; Curtis, R. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem., 2005, 48 (25), 8045-8054. (Pubitemid 41798434)
272. Trapp, J.; Jochum, A.; Meier, R.; Saunders, L.; Marshall, B.; Kunick, C.; Verdin, E.; Goekjian, P.; Sippl, W.; Jung, M. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J. Med. Chem., 2006, 49 (25), 7307-7316. (Pubitemid 44913391)
273. Lawson, M.; Uciechowska, U.; Schemies, J.; Rumpf, T.; Jung, M.; Sippl, W. Inhibitors to understand molecular mechanisms of NAD(+)-dependent deacetylases (sirtuins). Biochim. Biophys. Acta, 2010, 1799 (10-12), 726-739.
274. Trapp, J.; Meier, R.; Hongwiset, D.; Kassack, M.U.; Sippl, W.; Jung, M. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). Chem. Med. Chem., 2007, 2 (10), 1419-1431.
275. Brooks, C.L.; Gu W. p53 Activation: A case against Sir. Cancer Cell, 2008, 13(5), 377-378. (Pubitemid 351609448)
276. Oh, W.K.; Cho, K.B.; Hien, T.T.; Kim, T.H.; Kim, H.S.; Dao, T.T.; Han, H.K.; Kwon, S.M.; Ahn, S.G.; Yoon, J.H.; Kim, T.H.; Kim, Y.G.; Kang, K.W. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via down-regulation of multidrug resistance 1. Mol. Pharmacol., 2010, 78 (5), 855-864.
277. Cole, P.A. Chemical probes for histone-modifying enzymes. Nat. Chem. Biol., 2008, 4 (10), 590-597.
278. Grubisha, O.; Smith, B.C.; Denu, J.M. Small molecule regulation of Sir2 protein deacetylases. FEBS J., 2005, 272 (18), 4607-4616. (Pubitemid 41366985)
279. Smith, B.C.; Hallows, W.C.; Denu, J.M. Mechanisms and molecular probes of sirtuins. Chem. Biol., 2008, 15 (10), 1002-1013.
280. Schemies, J.; Sippl, W.; Jung, M. Histone deacetylase inhibitors that target tubulin. Cancer Lett., 2009, 280 (2), 222-232.
281. Blum, C.A.; Ellis, J.L.; Loh, C.; Ng, P.Y.; Perni, R.B.; Stein, R.L. SIRT1 modulation as a novel approach to the treatment of diseases of aging. J. Med. Chem., 2011, 54 (2), 417-432.
282. Kalle, A.M.; Mallika, A.; Badiger, J.; Alinakhi,T.; Alukdar, P.; Sachchidanand. Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells. Biochem. Biophys. Res. Commun., 2010, 401 (1), 13-19.
283. Pesnot, T.; Kempter, J.; Schemies, J.; Pergolizzi, G.; Uciechowska, U.; Rumpf, T.; Sippl, W.; Jung, M.; Wagner, G.K. Two-step synthesis of novel, bioactive derivatives of the ubiquitous cofactor nicotinamide adenine dinucleotide (NAD). J. Med. Chem., 2011, 54 (10), 3492-3499.
284. Schlicker, C.; Boanca, G.; Lakshminarasimhan, M.; Steegborn, C. Structurebased development of novel sirtuin inhibitors. Aging (Albany NY)., 2011, 3 (9), 852-872.
285. Fatkins, D.G.; Zheng, W. Substituting N(epsilon)-thioacetyl-lysine for N(epsilon)-acetyl-lysine in peptide substrates as a general approach to inhibiting human NAD(+)-dependent protein deacetylases. Int. J. Mol. Sci., 2008, 9 (1), 1-11. (Pubitemid 351263327)
286. Hirsch, B.M.; Zheng, W. Sirtuin mechanism and inhibition: Explored with N(e)-acetyl-lysine analogs. Mol. Biosyst., 2011, 7 (1), 16-28.
287. Heltweg, B.; Gatbonton, T.; Schuler, A.D.; Posakony, J.; Li, H.; Goehle, S.; Kollipara, R.; Depinho, R.A.; Gu, Y.; Simon, J.A.; Bedalov, A. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res., 2006, 66 (8), 4368-4377.